Seaport presents new meta-analysis examining the impact of clinical trial design factors on placebo response in generalized ...
Generalized anxiety disorder affects 1 in 20 U.S. adults. Those with serious symptoms may isolate themselves to the point they rarely leave their home and are unable to work and build meaningful ...
- Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results